Metropolis Acquires Ambika Pathology To Boost Maharashtra Presence

19 Sep 2025 CW Team

Established in 1995 by Dr Rajendra Sadashiv Patil, Ambika Pathology is one of the leading diagnostic providers in the region. It operates a central laboratory supported by 12 patient touchpoints and offers a wide range of tests. Nearly 75 per cent of its revenue comes from walk-in B2C patients, reflecting its strong trust among patients and clinicians in Kolhapur and neighbouring towns.

The acquisition forms part of Metropolis’ “String of Pearls” strategy, which focuses on building regional clusters and improving access to advanced diagnostics across India. The Kolhapur facility will strengthen the company’s Western Maharashtra network, where it already operates 19 laboratories across Pune, Sangli, Satara, Solapur, Nashik, Ahmednagar and Kolhapur, supported by over 200 patient service centres and a growing franchise base.

Ameera Shah, Promoter and Executive Chairperson of Metropolis, said: “Maharashtra contributes nearly 40 per cent of our revenues, making it a key growth market. Ambika Pathology strengthens our regional presence and supports our ambition to make high-quality diagnostics accessible to more communities.”

Surendran Chemmenkotil, Managing Director of Metropolis, added: “Kolhapur is a critical healthcare hub. Ambika Pathology will be developed into a mini regional reference lab, enhancing our specialised diagnostics capabilities and enabling better outcomes through operational excellence and digital innovation.”

Dr Rajendra Patil, Founder of Ambika Pathology, commented: “Joining Metropolis brings global standards of science and technology to our region. This collaboration will widen the scope of specialised tests and create new opportunities for patients and professionals in Western Maharashtra.”

Metropolis Healthcare Limited (NSE: METROPOLIS | BSE: 542650), India’s second-largest pathology laboratory chain led by Ameera Shah, has completed its fourth acquisition in the past 10 months with the addition of Dr R.S. Patil’s Ambika Pathology Laboratory in Kolhapur. The NABL-accredited facility has joined the Metropolis network through a Business Transfer Agreement.Established in 1995 by Dr Rajendra Sadashiv Patil, Ambika Pathology is one of the leading diagnostic providers in the region. It operates a central laboratory supported by 12 patient touchpoints and offers a wide range of tests. Nearly 75 per cent of its revenue comes from walk-in B2C patients, reflecting its strong trust among patients and clinicians in Kolhapur and neighbouring towns.The acquisition forms part of Metropolis’ “String of Pearls” strategy, which focuses on building regional clusters and improving access to advanced diagnostics across India. The Kolhapur facility will strengthen the company’s Western Maharashtra network, where it already operates 19 laboratories across Pune, Sangli, Satara, Solapur, Nashik, Ahmednagar and Kolhapur, supported by over 200 patient service centres and a growing franchise base.Ameera Shah, Promoter and Executive Chairperson of Metropolis, said: “Maharashtra contributes nearly 40 per cent of our revenues, making it a key growth market. Ambika Pathology strengthens our regional presence and supports our ambition to make high-quality diagnostics accessible to more communities.”Surendran Chemmenkotil, Managing Director of Metropolis, added: “Kolhapur is a critical healthcare hub. Ambika Pathology will be developed into a mini regional reference lab, enhancing our specialised diagnostics capabilities and enabling better outcomes through operational excellence and digital innovation.”Dr Rajendra Patil, Founder of Ambika Pathology, commented: “Joining Metropolis brings global standards of science and technology to our region. This collaboration will widen the scope of specialised tests and create new opportunities for patients and professionals in Western Maharashtra.”

Infrastructure Transport

06 Feb 2026

Lucknow Metro East-West Corridor Consultancy Contract Awarded

The Uttar Pradesh Metro Rail Corporation has awarded the first construction-related consultancy contract for the Lucknow Metro East West Corridor to a joint venture of AYESA Ingenieria Arquitectura SAU and AYESA India Pvt Ltd. The firm was declared the lowest bidder for the Detailed Design Consultant contract for Lucknow Metro Line-2 under Phase 1B and the contract was recommended following the financial bid. The contract is valued at Rs 159.0 million (mn), covering design services for the corridor. Lucknow Metro Line-2 envisages the construction of an 11.165 kilometre corridor connecting Cha..

Infrastructure Urban

06 Feb 2026

Div Com Kashmir Urges Fast Tracking Of Jhelum Water Transport Project

The Divisional Commissioner of Kashmir has called for the fast-tracking of the Jhelum water transport project, urging district administrations and relevant agencies to accelerate planning and clearances. In a meeting convened at the divisional headquarters, the commissioner instructed officials from irrigation, public health engineering and municipal departments to prioritise the project and coordinate survey and design work. The directive emphasised removal of administrative bottlenecks and close monitoring to ensure timely mobilisation of resources and contractors. Officials were told to in..

Infrastructure Urban

06 Feb 2026

Interarch Reports Strong Q3 And Nine Month Results

Interarch Building Solutions Limited reported unaudited results for the third quarter and nine months ended 31 December 2025, recording strong revenue growth driven by execution and a robust order book. Net revenue for the third quarter rose by 43.7 per cent to Rs 5.225 billion (bn), compared with Rs 3.636 bn a year earlier, reflecting heightened demand in pre-engineered building projects. The company’s total order book as at 31 January 2026 stood at Rs 16.85 bn, supporting near-term visibility. EBITDA excluding other income for the quarter increased by 43.2 per cent to Rs 503 million (mn),..